{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.7","upperLimit":"95.3","value":"86.7"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.9","upperLimit":"98.6","value":"90.5"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.8","upperLimit":"92.5","value":"78.1"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"}],"units":"Participants"}],"description":"Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.","dispersionType":"95% Confidence Interval","groups":[{"description":"High risk prostate cancer participants planned for radical prostatectomy with pelvic lymph node dissection were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection.","id":"OG000","title":"High Risk Prostate Cancer (Cohort A)"}],"paramType":"NUMBER","populationDescription":"The Evaluable Set of high risk prostate cancer participants (Cohort A) includes those who received 18F-DCFPyL, had a prostatectomy or lymphadenectomy, and provided a 18F-DCFPyL PET/CT image result and a corresponding histopathology result.","reportingStatus":"POSTED","timeFrame":"Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.","title":"Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}